WO2001027072A1 - Forme hydratee du chlorhydrate de n-[3[[2-(3,4-dimethoxyphenyl)ethyle]amino]propyle]-4-nitro benzamide et son utilisation dans des compositions pharmaceutiques - Google Patents

Forme hydratee du chlorhydrate de n-[3[[2-(3,4-dimethoxyphenyl)ethyle]amino]propyle]-4-nitro benzamide et son utilisation dans des compositions pharmaceutiques Download PDF

Info

Publication number
WO2001027072A1
WO2001027072A1 PCT/GB2000/003862 GB0003862W WO0127072A1 WO 2001027072 A1 WO2001027072 A1 WO 2001027072A1 GB 0003862 W GB0003862 W GB 0003862W WO 0127072 A1 WO0127072 A1 WO 0127072A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
propyl
dimethoxyphenyl
amino
hydrochloride
Prior art date
Application number
PCT/GB2000/003862
Other languages
English (en)
Inventor
Ian Robert Lynch
Graham Ralph Slater
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP00966293A priority Critical patent/EP1218335A1/fr
Priority to AU76738/00A priority patent/AU7673800A/en
Priority to JP2001530093A priority patent/JP2003511438A/ja
Publication of WO2001027072A1 publication Critical patent/WO2001027072A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are 15 oxygen or nitrogen;
  • A represents a Ci .4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C1 _6 alkyl groups;
  • R represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of the group of R2, 3 and R4 represents nitro the remaining members of the 20 group of R_2, R3 and R4 represent hydrogen;
  • X represents a -CO-NH- moiety
  • Z represents C2.4 n-alkylene group wherein each carbon is optionally substituted by 1 or
  • Example 2 of WO 96/13479 is the non-solvated hydrochloride salt, N-[3-[[2-(3,4- 25 dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride (hereinafter also referred to as 'the Hydrochloride 1 ), the disclosed melting point of which is 141-2°C.
  • N-[3-[[2-(3,4- 30 dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride exists in a novel hydrated form which form is particularly suitable for bulk preparation and handling and is also indicated to have superior formulation properties.
  • This novel hydrated form can be prepared by an efficient, economic and reproducible process particularly suited to large scale preparation.
  • the novel form also has useful pharmaceutical properties and is considered to be a useful anti-arrhythmic agent having combined Class Ill/Class IN anti-arrhythmic properties, therefore showing an improved pharmacological profile over pure class III anti-arrhythmic agents, in particular showing a low proarrhythmic potential, readily .restoring the contractile function of the ischaemic myocardium.
  • the present invention provides hydrated N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride (hereinafter also referred to as 'Compound (I)') characterised in that it:
  • Compound (I) comprises from 1.8 to 2.3 or 1.9 to 2.1 molar equivalents of water, especially 2.0 molar equivalents.
  • the present invention encompasses Compound (I) isolated in a purified form or in an impure form, such as when admixed with other materials, for example the known form of the Hydrochloride or any other material.
  • Compound (I) is in a puried form, especially a crystalline form.
  • the invention also provides a process for preparing hydrated N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride, characterised in that N- [3 - [[2-(3 ,4-dimethoxypheny l)ethyl] aminojpropyl] -4-nitrobenzamide hydrochloride is hydrated in the presence of a molar excess of water.
  • Suitable hydration methods include conventional hydration methods such as crystallisation, including recrystallisation, particularly via rapid cooling, of the Hydrochloride from water or an aqueous solvent.
  • a suitable aqueous solvent is an aqueous organic solvent such as an aqueous ethanol, for example a 9:1 mixture by volume of ethanol and water.
  • Crystallisation and any recrystallisation is generally carried out at low to ambient temperature, suitably at ambient temperature.
  • the crystallisation and any recrystallisation is carried out by rapid cooling.
  • the crystallisation or recrystallisation is carried out by cooling of the aqueous ethanolic solution of the Hydrochloride, for example by immersing the solution in an ice-bath.
  • the aqueous ethanol solution is prepared by dissolving the Hydrochloride in the aqueous ethanol at an elevated temperature, for example at the reflux temperature of the solvent.
  • Compound (I) is prepared from a solution of the Hydrochloride in aqueous ethanol at an elevated temperature such as 60°C, Compound (I) is then formed by cooling.
  • the Hydrochloride is prepared according to known procedures such as those disclosed in WO 96/13479. The disclosures of WO 96/13479 are incorporated herein by reference.
  • 'aqueous solvent' includes single organic solvents or mixtures of organic solvents which contain sufficient water to provide product with 1.7 to 2.4, especially 1.8 to 2.3 or 1.9 to 2.1 and preferably 2.0, molar equivalents of water ('the required level' or 'the required amount' of water); usually, the level of water present is in excess of the required level.
  • cardiac arrhythmia relates to any variation from the normal rhythm of heart beat, including, without limitation, sinus arrhythmia, premature heartbeat, heartblock, fibrillation, flutter, tachycardia, paroxysmal tachycardia and premature ventricular contractions.
  • the present invention accordingly provides Compound (I) for use as an active therapeutic substance.
  • the present invention provides a Compound (I) for use in the treatment of and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders.
  • Compound (I) may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising Compound (I) and a pharmaceutically acceptable carrier therefor.
  • Compound (I) is normally administered in unit dosage form.
  • An amount effective to treat the disorder hereinbefore described depends upon such factors as the efficacy of a Compound (I) chosen, the nature and severity of the disorders being treated and the weight of the mammal.
  • a unit dose will normally contain 0.1 to 500 mg for example 2 to 50 mg, of the compound of the invention.
  • Unit doses will normally be administered once or more than once a day, for example 2,3,4,5 or 6 times a day, more usually 2 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 2500 mg, more usually 1 to 1000 mg, for example 1 to 200 mg, that is in the range of approximately 0.02 to 3 mg/kg/day, more usually 0.1 to 3 mg/kg/day, for example 0.15 to 2 mg/kg/day.
  • the active compound may be administered by any suitable route, e.g. by the oral, parenteral or topical routes.
  • the compound will normally be employed in the form of a pharmaceutical composition in association with a human or veterinary pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.
  • compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, i ⁇ jectable and infusable solutions or suspensions, suppositories and transdermal devices.
  • Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
  • the composition may be in the form of a transdermal ointment or patch for systemic delivery of the compound and may be prepared in a conventional manner, for example, as described in the standard textbooks such as
  • compositions may contain further active agents such as anti-hypertensive agents and diuretics.
  • active agents such as anti-hypertensive agents and diuretics.
  • the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
  • the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
  • the present invention further provides a method for the treatment and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Compound (I) to a human or non-human mammal in need thereof.
  • the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
  • Compound (I) may be taken in doses, such as those described above. Similar dosage regimens are suitable for the treatment and/or prophylaxis of non-human mammals.
  • the present invention provides the use of Compound (I) for the manufacture of a medicament for the treatment of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders. No adverse toxicological effects are indicated when Compound (I) is administered in the above mentioned dosage ranges.
  • Step size 0.020 °2 ⁇
  • the infrared absorption spectrum of a mineral oil dispersion of compound (I) was obtained using a Perkin-Elmer PE2000 FTIR spectrometer at 2 cm" 1 resolution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne une forme hydratée du chlorhydrate de N-[3-[[2-(3,4-diméthoxyphényl)éthyle]amino]propyle]-4-nitro benzamide, un procédé de préparation d'un tel composé et son utilisation en thérapie.
PCT/GB2000/003862 1999-10-08 2000-10-06 Forme hydratee du chlorhydrate de n-[3[[2-(3,4-dimethoxyphenyl)ethyle]amino]propyle]-4-nitro benzamide et son utilisation dans des compositions pharmaceutiques WO2001027072A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00966293A EP1218335A1 (fr) 1999-10-08 2000-10-06 Forme hydratee du chlorhydrate de n- 3 2-(3,4-dimethoxyphenyl)ethyle]amino]propyle]-4-nitro benzamide et son utilisation dans des compositions pharmaceutiques
AU76738/00A AU7673800A (en) 1999-10-08 2000-10-06 Hydrated N-(3-((2-(3,4-dimethoxyphenyl) ethyl) amino) propyl) -4-nitro benzamidehydrochloride and its use in pharmaceutical compositions
JP2001530093A JP2003511438A (ja) 1999-10-08 2000-10-06 水和ｎ−［３−［［２−（３，４−ジメトキシフェニル）エチル］アミノ］プロピル］−４−ニトロベンズアミド塩酸塩およびその医薬組成物中における使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923934.5A GB9923934D0 (en) 1999-10-08 1999-10-08 Novel pharmaceutical
GB9923934.5 1999-10-08

Publications (1)

Publication Number Publication Date
WO2001027072A1 true WO2001027072A1 (fr) 2001-04-19

Family

ID=10862443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003862 WO2001027072A1 (fr) 1999-10-08 2000-10-06 Forme hydratee du chlorhydrate de n-[3[[2-(3,4-dimethoxyphenyl)ethyle]amino]propyle]-4-nitro benzamide et son utilisation dans des compositions pharmaceutiques

Country Status (5)

Country Link
EP (1) EP1218335A1 (fr)
JP (1) JP2003511438A (fr)
AU (1) AU7673800A (fr)
GB (1) GB9923934D0 (fr)
WO (1) WO2001027072A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520803A (ja) * 2002-01-09 2005-07-14 エミスフェアー・テクノロジーズ・インク ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013479A1 (fr) * 1994-10-26 1996-05-09 Smithkline Beecham Laboratoires Pharmaceutiques Nitro-benzamides utilisables comme agents antiarythmiques
WO1998043947A1 (fr) * 1997-03-27 1998-10-08 Smithkline Beecham Plc Nitro-benzamide utile en tant qu'agent anti-arythmie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013479A1 (fr) * 1994-10-26 1996-05-09 Smithkline Beecham Laboratoires Pharmaceutiques Nitro-benzamides utilisables comme agents antiarythmiques
WO1998043947A1 (fr) * 1997-03-27 1998-10-08 Smithkline Beecham Plc Nitro-benzamide utile en tant qu'agent anti-arythmie

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520803A (ja) * 2002-01-09 2005-07-14 エミスフェアー・テクノロジーズ・インク ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体
US7893297B2 (en) 2002-01-09 2011-02-22 Emisphere Technologies, Inc. Amorphous sodium 4-[4-chloro-2-hydroxybenzoyl)amino]butanoate

Also Published As

Publication number Publication date
JP2003511438A (ja) 2003-03-25
GB9923934D0 (en) 1999-12-08
EP1218335A1 (fr) 2002-07-03
AU7673800A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
US20050288513A1 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
HU184966B (en) Process for producing phenyl-piperazine derivatives of anti-agression activity
ES2203453T3 (es) Polimorfo de sal del acido maleico de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bentil)tiazolidina-2,4-diona.
US20040097553A1 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020099081A1 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
ES2218146T3 (es) Derivado de tiazolidinadiona y su uso como antidiabetico.
AU741476B2 (en) Nitro-benzamide useful as anti-arrhythmic agent
ES2214267T3 (es) Derivado de tiazolidindiona y su uso como antidiabetico.
EP1218335A1 (fr) Forme hydratee du chlorhydrate de n- 3 2-(3,4-dimethoxyphenyl)ethyle]amino]propyle]-4-nitro benzamide et son utilisation dans des compositions pharmaceutiques
WO2001027071A1 (fr) Hydrochlorure de benzamide n-[3-[[2-(3,4-dimethexyphenyl)ethyl]amino]propyl]-4-nitro polymorphe
US20010056207A1 (en) Nitro-benzamide useful as anti-arrhythmic agent
EP0719263B1 (fr) Derives heterocycliques de carboxamide ayant une activite antiarythmique
MXPA99008872A (en) Nitro-benzamide useful as anti-arrhythmic agent
CZ341899A3 (cs) Nitrobenzamid vhodný jako antiarytmický přípravek
WO1996027595A1 (fr) Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2001 530093

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000966293

Country of ref document: EP

Ref document number: 10089657

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000966293

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000966293

Country of ref document: EP